| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2015PLoSO..1017227G |
| P356 | DOI | 10.1371/JOURNAL.PONE.0117227 |
| P932 | PMC publication ID | 4331506 |
| P698 | PubMed publication ID | 25688555 |
| P5875 | ResearchGate publication ID | 272511951 |
| P50 | author | Margaret E. Ackerman | Q57012155 |
| Michael B Battles | Q47115798 | ||
| P2093 | author name string | Sebastian K Grimm | |
| P2860 | cites work | Few and far between: how HIV may be evading antibody avidity | Q21090507 |
| Gene Designer: a synthetic biology tool for constructing artificial DNA segments | Q21284253 | ||
| The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens | Q22242262 | ||
| Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | Q24561905 | ||
| DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution | Q24562755 | ||
| Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1 | Q24645530 | ||
| Antibody Recognition and Neutralization Determinants on Domains I and II of West Nile Virus Envelope Protein | Q27477718 | ||
| A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies | Q27485578 | ||
| Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus | Q27644501 | ||
| Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies | Q27644515 | ||
| Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 | Q27658449 | ||
| Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope | Q27664365 | ||
| Elicitation of structure-specific antibodies by epitope scaffolds | Q27664711 | ||
| Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding | Q27670829 | ||
| Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing | Q27671696 | ||
| Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold | Q27675190 | ||
| Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast. | Q51304377 | ||
| Yeast surface display of a noncovalent MHC class II heterodimer complexed with antigenic peptide. | Q51356858 | ||
| Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency | Q56902099 | ||
| Direct random mutagenesis of gene-sized DNA fragments using polymerase chain reaction | Q72141004 | ||
| Secretion-and-capture cell-surface display for selection of target-binding proteins | Q83608801 | ||
| Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors | Q27677104 | ||
| Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer | Q27680496 | ||
| Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer | Q27680497 | ||
| Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers | Q27683553 | ||
| Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. | Q28217208 | ||
| DNA shuffling of a family of genes from diverse species accelerates directed evolution | Q28259708 | ||
| A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies | Q28299280 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 | Q29619512 | ||
| Fine epitope mapping of monoclonal antibodies against hemagglutinin of a highly pathogenic H5N1 influenza virus using yeast surface display | Q30402648 | ||
| A flow cytometric assay for screening improved heterologous protein secretion in yeast | Q30820875 | ||
| Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity | Q30923970 | ||
| Production of complex human glycoproteins in yeast | Q31155283 | ||
| Yeast surface display for directed evolution of protein expression, affinity, and stability | Q31826513 | ||
| An episomal expression vector for screening mutant gene libraries in Pichia pastoris | Q33215505 | ||
| Isolating and engineering human antibodies using yeast surface display | Q33280948 | ||
| Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling | Q33349284 | ||
| Antibody binding site mapping of SARS-CoV spike protein receptor-binding domain by a combination of yeast surface display and phage peptide library screening | Q33516972 | ||
| Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals | Q33526340 | ||
| Characteristics of the earliest cross-neutralizing antibody response to HIV-1. | Q33798076 | ||
| Rational antibody-based HIV-1 vaccine design: current approaches and future directions | Q33937285 | ||
| Medicine. The need for a global HIV vaccine enterprise | Q34209402 | ||
| B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study | Q34273373 | ||
| Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. | Q34361680 | ||
| Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast | Q34480254 | ||
| Induction of immunity to human immunodeficiency virus type-1 by vaccination | Q34540645 | ||
| Humanization of yeast to produce complex terminally sialylated glycoproteins | Q34564538 | ||
| Increased functional stability and homogeneity of viral envelope spikes through directed evolution | Q34611144 | ||
| Protein folding and quality control in the endoplasmic reticulum: Recent lessons from yeast and mammalian cell systems | Q35160159 | ||
| Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies | Q36016347 | ||
| HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. | Q36132728 | ||
| Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape | Q36388754 | ||
| Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies | Q36750045 | ||
| Yeast surface display for screening combinatorial polypeptide libraries | Q36865126 | ||
| Highly L and D enantioselective variants of horseradish peroxidase discovered by an ultrahigh-throughput selection method | Q36976667 | ||
| Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation | Q36977531 | ||
| Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. | Q37033291 | ||
| An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site | Q37069430 | ||
| Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation | Q37318042 | ||
| Toward an antibody-based HIV-1 vaccine | Q37613695 | ||
| Challenges for structure-based HIV vaccine design | Q37667763 | ||
| Correlates of protection induced by vaccination | Q37750121 | ||
| Engineering of glycosylation in yeast and other fungi: current state and perspectives | Q37768357 | ||
| Limitations to the structure-based design of HIV-1 vaccine immunogens | Q37910841 | ||
| Emerging concepts on the role of innate immunity in the prevention and control of HIV infection | Q37955261 | ||
| Vaccine design: emerging concepts and renewed optimism | Q38087785 | ||
| Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step | Q38335402 | ||
| Mapping the journey to an HIV vaccine | Q38565206 | ||
| Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers | Q39001126 | ||
| Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates | Q39484948 | ||
| A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure | Q39588870 | ||
| Genotype-specific neutralization and protection by antibodies against dengue virus type 3. | Q39668466 | ||
| Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein | Q39684388 | ||
| Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization | Q39723388 | ||
| Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. | Q40429324 | ||
| A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. | Q40757568 | ||
| Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. | Q45149860 | ||
| Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology | Q46170507 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | directed evolution | Q440681 |
| protein evolution | Q59870539 | ||
| P304 | page(s) | e0117227 | |
| P577 | publication date | 2015-02-17 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies | |
| P478 | volume | 10 |
| Q47436657 | Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6. |
| Q47765958 | Directed Evolution of Glycopeptides Using mRNA Display |
| Q58601813 | Display of the HIV envelope protein at the yeast cell surface for immunogen development |
| Q90024145 | Identification of variant HIV envelope proteins with enhanced affinities for precursors to anti-gp41 broadly neutralizing antibodies |
| Q55518743 | Towards conformational fidelity of a quaternary HIV-1 epitope: computational design and directed evolution of a minimal V1V2 antigen. |
Search more.